Lipodystrophy & Metabolic Complications: Research: 2002

Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy (July 10, 2002)
In Journal of the American Medical Association
Fat Redistribution and Metabolic Changes With a Nucleoside-Reverse Transcriptase Inhibitor, Non-NRTI, or Protease Inhibitor-Based Regimen: FRAMS Substudy of the Atlantic Study (July 10, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
Quantification of Mitochondrial DNA in Human Cells Using Real-Time PCR With Fluorogenic Reporters (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
Disturbing Metabolic Disturbances: Basic Science (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
Disturbing Metabolic Disturbances: Clinical Impact (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
Special Retrovirus Update: Lipodystrophy (March 28, 2002)
To read PDF, click here.
In STEP Ezine, from Seattle Treatment Education Project
On TheBodyPRO.com
Lipoatrophy and Antiretroviral Drug Changes (March 8, 2002)
In AIDS Treatment News, from AIDS Treatment News
On TheBodyPRO.com
9th Retrovirus Conference Coverage: Lipodystrophy Definition (Spring 2002)
In STEP Perspective, from Seattle Treatment Education Project
9th Retrovirus Conference Coverage: Lipodystrophy Treatment (Spring 2002)
In STEP Perspective, from Seattle Treatment Education Project
9th Retrovirus Conference Coverage: Lipodystrophy: To Switch or Not to Switch? (Spring 2002)
In STEP Perspective, from Seattle Treatment Education Project
Lipodystrophy Update (March 2002)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
On TheBodyPRO.com
A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Combivir/Abacavir/Nelfinavir, or Stavudine/Lamivudine/NFV (ESS40002) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Switching Stavudine or Zidovudine to Abacavir for HIV Lipoatrophy: A Randomized, Controlled, Open-Label, Multicentre, 24-Week Study (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com

< Previous | 1 | 2

More Most Viewed Articles

HIV Tools You Can Use

Track Your CD4 Count, Viral Load and More: Use TheBody.com's Health Tracker

TheBody.com's New! TheBody.com App
TheBody.com's Medication and Health Reminders
TheBody.com's Facebook, Widgets, RSS Feeds and Twitter
Are You at Risk for HIV? Take Our Quiz!
U.S. ASO Finder U.S. ASO Listings
International ASOs

The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.